SEC Form 4 · accession 0001708848-19-000001
Lexaria Bioscience Corp. · LXRP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Allan Horst Spissinger
Officer — Chief Financial Officer
Period of report
Jan 20, 2010
Accepted (ET)
Feb 15, 2019 · 2:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001348362
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| common shares | Feb 15, 2019 | M | 50,000 | $0.37 | A | 119,116 | D | |
| common shares | holding | — | — | — | 69,166 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options | $0.37 | Feb 15, 2019 | M | 50,000 | D | Jun 1, 2017 | Jun 1, 2022 | Common Shares | 50,000 | 650,000 | D |
| Stock Options | $0.37 | holding | — | — | — | Jun 1, 2017 | Jun 1, 2022 | Common Shares | 200,000 | 200,000 | D |
| Stock Options | $0.83 | holding | — | — | — | Dec 1, 2017 | Dec 1, 2022 | Common Shares | 200,000 | 400,000 | D |
| Stock Options | $1.53 | holding | — | — | — | May 31, 2018 | May 31, 2023 | Common Shares | 300,000 | 700,000 | D |